Real-World check: Nivolumab's survival numbers in greek lung cancer patients
NCT ID NCT05034926
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study looked at 212 adults with advanced non-small cell lung cancer who received the immunotherapy drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 1, 2, and 3 years after starting treatment. The goal was to see how well the drug works in real-world clinics in Greece and Cyprus, not in a controlled trial setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Athens, 11527, Greece
-
Local Institution - 0002
Stróvolos, 2012, Cyprus
Conditions
Explore the condition pages connected to this study.